CFD merupakan instrumen yang rumit dan memiliki risiko tinggi kehilangan uang secara cepat karena adanya pengaruh leverage. 84% akun investor ritel mengalami kerugian saat melakukan kegiatan perdagangan CFD dengan penyedia ini. Anda harus mempertimbangkan apakah Anda memahami cara kerja CFD dan apakah Anda mampu menerima risiko tinggi kehilangan uang.
US Bahasa Indonesia
Negara • United States
    Entitas • The products and services listed on this website are not available to US residents.
    English العَرَبِيَّة Bahasa Indonesia Български Čeština Dansk Deutsch Eesti ελληνικά Español Français Hrvatski Italiano Latviešu Lietuvių Magyar Nederlands Polski Português Română Русский Slovenčina Slovenščina Suomi Svenska Tiếng Việt ไทย 简体中文 繁體中文

    Perdagangan Lineage Cell Therapeutics, Inc. - LCTX CFD

    1.25
    4.58%
    • Summary
    • Historical Data
    • Events
    • Income Statement
    • Balance Sheet
    • Cash Flow
    • Ownership
    Trading Conditions
    Spread 0.09
    Biaya inap posisi Long

    Long position overnight fee

    Margin. Your investment $1,000.00
    Biaya Overnight -0.025457 %
    Charges from borrowed part ($-1.02)
    Trade size with leverage ~ $5,000.00
    Money from leverage ~ $4,000.00
    Kunjungi platform
    		-0.025457%
    Biaya inap posisi short

    Short position overnight fee

    Margin. Your investment $1,000.00
    Biaya Overnight 0.003235 %
    Charges from borrowed part ($0.13)
    Trade size with leverage ~ $5,000.00
    Money from leverage ~ $4,000.00
    Kunjungi platform
    		0.003235%
    Waktu biaya inap 21:00 (UTC)
    Kuantitas min. yang diperdagangkan 1
    Mata uang USD
    Margin 20%
    Bursa efek United States of America
    Komisi perdagangan 0%

    *Information provided by Capital.com

    Lineage Cell Therapeutics Inc ESG Risk Ratings

    High Medium Low Negligible

    ‘C’ score indicates satisfactory relative ESG performance and moderate degree of transparency in reporting material ESG data publicly.

    Key Stats
    Prev. Close* 1.31
    Open* 1.32
    1-Year Change* -10.81%
    Day's Range* 1.25 - 1.33
    52 wk Range 1.02-1.79
    Average Volume (10 days) 413.10K
    Average Volume (3 months) 7.57M
    Market Cap 229.74M
    P/E Ratio -100.00K
    Shares Outstanding 170.17M
    Revenue 11.85M
    EPS -0.14
    Dividend (Yield %) N/A
    Beta 1.69
    Next Earnings Date Aug 9, 2023

    All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com

    • Last Week
    • Last Month
    • Last Year
    • Last two Years
    • Max
    • Daily
    • Weekly
    • Monthly
    Date Close Change Change (%) Open High Low
    Jun 7, 2023 1.31 -0.03 -2.24% 1.34 1.35 1.31
    Jun 6, 2023 1.32 0.06 4.76% 1.26 1.36 1.26
    Jun 5, 2023 1.25 -0.01 -0.79% 1.26 1.29 1.22
    Jun 2, 2023 1.29 0.04 3.20% 1.25 1.31 1.24
    Jun 1, 2023 1.25 0.02 1.63% 1.23 1.27 1.22
    May 31, 2023 1.24 0.03 2.48% 1.21 1.27 1.21
    May 30, 2023 1.22 -0.06 -4.69% 1.28 1.28 1.22
    May 26, 2023 1.26 0.01 0.80% 1.25 1.27 1.25
    May 25, 2023 1.25 -0.02 -1.57% 1.27 1.29 1.25
    May 24, 2023 1.29 0.01 0.78% 1.28 1.32 1.28
    May 23, 2023 1.29 -0.04 -3.01% 1.33 1.35 1.29
    May 22, 2023 1.32 -0.03 -2.22% 1.35 1.36 1.32
    May 19, 2023 1.33 0.01 0.76% 1.32 1.36 1.32
    May 18, 2023 1.31 -0.02 -1.50% 1.33 1.36 1.31
    May 17, 2023 1.34 0.00 0.00% 1.34 1.36 1.34
    May 16, 2023 1.32 0.00 0.00% 1.32 1.36 1.31
    May 15, 2023 1.36 0.03 2.26% 1.33 1.37 1.32
    May 12, 2023 1.35 -0.04 -2.88% 1.39 1.41 1.35
    May 11, 2023 1.39 0.00 0.00% 1.39 1.41 1.37
    May 10, 2023 1.40 -0.02 -1.41% 1.42 1.46 1.39

    Lineage Cell Therapeutics, Inc. Events

    Time (UTC) Country Event
    Wednesday, August 9, 2023

    Time (UTC)

    10:59

    Country

    US

    Event

    Q2 2023 Lineage Cell Therapeutics Inc Earnings Release
    Q2 2023 Lineage Cell Therapeutics Inc Earnings Release

    Forecast

    -

    Previous

    -
    Wednesday, November 8, 2023

    Time (UTC)

    10:59

    Country

    US

    Event

    Q3 2023 Lineage Cell Therapeutics Inc Earnings Release
    Q3 2023 Lineage Cell Therapeutics Inc Earnings Release

    Forecast

    -

    Previous

    -
    View all events
    • Annual
    • Quarterly
    2022 2021 2020 2019 2018
    Total revenue 14.703 4.341 1.826 3.515 4.988
    Revenue 14.703 4.341 1.826 3.515 4.988
    Cost of Revenue, Total 0.728 1.426 0.385 0.412 0.302
    Gross Profit 13.975 2.915 1.441 3.103 4.686
    Total Operating Expense 37.223 53.029 28.273 42.391 -31.728
    Selling/General/Admin. Expenses, Total 22.508 18.212 15.571 24.031 24.726
    Research & Development 13.887 33.714 11.117 15.948 18.755
    Unusual Expense (Income) 0 -0.523 0 -77.711
    Operating Income -22.52 -48.688 -26.447 -38.876 36.716
    Interest Income (Expense), Net Non-Operating -1.365 3.727 1.817 16.499 -82.531
    Other, Net -1.927 1.691 2.706 3.143 -1.315
    Net Income Before Taxes -25.812 -43.27 -21.924 -19.234 -47.13
    Net Income After Taxes -26.353 -43.27 -20.685 -11.827 -46.784
    Minority Interest 0.08 0.251 0.036 0.118 0.794
    Net Income Before Extra. Items -26.273 -43.019 -20.649 -11.709 -45.99
    Net Income -26.273 -43.019 -20.649 -11.709 -45.99
    Total Adjustments to Net Income
    Income Available to Common Excl. Extra. Items -26.273 -43.019 -20.649 -11.709 -45.99
    Income Available to Common Incl. Extra. Items -26.273 -43.019 -20.649 -11.709 -45.99
    Dilution Adjustment
    Diluted Net Income -26.273 -43.019 -20.649 -11.709 -45.99
    Diluted Weighted Average Shares 169.792 164.502 150.044 145.533 126.903
    Diluted EPS Excluding Extraordinary Items -0.15474 -0.26151 -0.13762 -0.08046 -0.3624
    Diluted Normalized EPS -0.15474 -0.26469 -0.13762 -0.08046 -0.75823
    Depreciation / Amortization 0.1 0.2 1.2 2 2.2
    Mar 2023 Dec 2022 Sep 2022 Jun 2022 Mar 2022
    Total revenue 2.386 1.915 2.998 4.553 5.237
    Revenue 2.386 1.915 2.998 4.553 5.237
    Cost of Revenue, Total 0.119 0.102 0.235 0.215 0.176
    Gross Profit 2.267 1.813 2.763 4.338 5.061
    Total Operating Expense 9.028 8.554 8.249 8.787 11.633
    Selling/General/Admin. Expenses, Total 4.724 4.348 4.422 5.27 8.469
    Research & Development 4.185 4.104 3.592 3.302 2.988
    Depreciation / Amortization
    Operating Income -6.642 -6.639 -5.251 -4.234 -6.396
    Interest Income (Expense), Net Non-Operating 0.45 -0.123 0.151 -0.658 -0.734
    Other, Net -0.015 0.4 -0.475 -1.89 0.037
    Net Income Before Taxes -6.207 -6.362 -5.575 -6.782 -7.093
    Net Income After Taxes -4.404 -6.362 -6.116 -6.782 -7.093
    Minority Interest 0.032 0.008 0.047 0.019 0.006
    Net Income Before Extra. Items -4.372 -6.354 -6.069 -6.763 -7.087
    Net Income -4.372 -6.354 -6.069 -6.763 -7.087
    Income Available to Common Excl. Extra. Items -4.372 -6.354 -6.069 -6.763 -7.087
    Income Available to Common Incl. Extra. Items -4.372 -6.354 -6.069 -6.763 -7.087
    Diluted Net Income -4.372 -6.354 -6.069 -6.763 -7.087
    Diluted Weighted Average Shares 170.127 170.002 169.786 169.731 169.647
    Diluted EPS Excluding Extraordinary Items -0.0257 -0.03738 -0.03574 -0.03985 -0.04177
    Dividends per Share - Common Stock Primary Issue 0 0 0 0
    Diluted Normalized EPS -0.0257 -0.03738 -0.03574 -0.03985 -0.04177
    Unusual Expense (Income) 0 0 0
    • Annual
    • Quarterly
    2022 2021 2020 2019 2018
    Total Current Assets 60 111.549 43.999 57.519 36.358
    Cash and Short Term Investments 57.875 58.358 41.562 30.716 30.741
    Cash & Equivalents 11.355 55.742 32.585 9.497 23.587
    Short Term Investments 46.52 2.616 8.977 21.219 7.154
    Total Receivables, Net 0.297 50.84 0.004 23.94 3.719
    Accounts Receivable - Trade, Net 0.297 50.84 0.004 0.044 0.891
    Prepaid Expenses 1.828 2.351 2.433 2.863 1.898
    Total Assets 123.664 174.545 107.949 125.478 101.66
    Property/Plant/Equipment, Total - Net 5.673 4.872 5.63 8.175 5.835
    Property/Plant/Equipment, Total - Gross 11.523 10.174 9.945 12.766 9.02
    Accumulated Depreciation, Total -5.85 -5.302 -4.315 -4.591 -3.185
    Intangibles, Net 46.692 46.822 47.032 48.248 3.125
    Long Term Investments 0 33.733
    Other Long Term Assets, Total 0.627 0.63 0.616 0.864 0.505
    Total Current Liabilities 18.981 47.116 7.769 6.494 6.812
    Accounts Payable 2.393 3.543 2.611 2.427 2.359
    Accrued Expenses 7.131 25.049 4.416 3.985 4.332
    Notes Payable/Short Term Debt 0 0 0.523 0 0
    Current Port. of LT Debt/Capital Leases 0.036 0.03 0.016 0.033 0.07
    Other Current Liabilities, Total 9.421 18.494 0.203 0.049 0.051
    Total Liabilities 50.325 82.324 11.75 12.519 7.82
    Total Long Term Debt 0.084 0.03 0.026 0.077 1.958
    Long Term Debt 0
    Capital Lease Obligations 0.084 0.03 0.026 0.077 1.958
    Minority Interest -1.403 -1.323 -1.072 -1.712 -1.594
    Other Liabilities, Total 30.587 34.425 2.951 4.345 0.644
    Total Equity 73.339 92.221 96.199 112.959 93.84
    Preferred Stock - Non Redeemable, Net 0 0 0
    Common Stock 440.28 434.529 393.944 387.062 354.27
    Retained Earnings (Accumulated Deficit) -363.37 -337.097 -294.078 -273.422 -261.856
    Treasury Stock - Common
    Other Equity, Total -3.571 -5.211 -3.667 -0.681 1.426
    Total Liabilities & Shareholders’ Equity 123.664 174.545 107.949 125.478 101.66
    Total Common Shares Outstanding 170.093 169.477 153.096 149.804 127.136
    Note Receivable - Long Term 0 22.104
    Goodwill, Net 10.672 10.672 10.672 10.672
    Deferred Income Tax 2.076 2.076 2.076 3.315
    Mar 2023 Dec 2022 Sep 2022 Jun 2022 Mar 2022
    Total Current Assets 49.655 60 68.509 74.026 81.872
    Cash and Short Term Investments 46.814 57.875 66.355 72.03 79.944
    Cash & Equivalents 15.451 11.355 24.752 70.857 78.062
    Short Term Investments 31.363 46.52 41.603 1.173 1.882
    Total Receivables, Net 0.203 0.297 0.434 0.707 0.515
    Accounts Receivable - Trade, Net 0.203 0.297 0.434 0.707 0.515
    Prepaid Expenses 2.638 1.828 1.72 1.289 1.413
    Total Assets 113.205 123.664 131.148 135.922 144.52
    Property/Plant/Equipment, Total - Net 5.584 5.673 4.652 3.869 4.548
    Property/Plant/Equipment, Total - Gross 11.694 11.523 10.464 9.414 10.135
    Accumulated Depreciation, Total -6.11 -5.85 -5.812 -5.545 -5.587
    Goodwill, Net 10.672 10.672 10.672 10.672 10.672
    Intangibles, Net 46.659 46.692 46.724 46.757 46.789
    Other Long Term Assets, Total 0.635 0.627 0.591 0.598 0.639
    Total Current Liabilities 17.225 18.981 22.739 25.091 24.593
    Accounts Payable 3.001 2.393 2.865 2.589 2.956
    Accrued Expenses 3.126 7.131 7.46 6.678 6.642
    Notes Payable/Short Term Debt 0 0 0 0 0
    Current Port. of LT Debt/Capital Leases 0.051 0.036 0.025 0.029 0.031
    Other Current Liabilities, Total 11.047 9.421 12.389 15.795 14.964
    Total Liabilities 42.755 50.325 52.2 53.075 57.973
    Total Long Term Debt 0.133 0.084 0.016 0.019 0.026
    Capital Lease Obligations 0.133 0.084 0.016 0.019 0.026
    Deferred Income Tax 0.273 2.076 2.076 2.076 2.076
    Minority Interest -1.435 -1.403 -1.395 -1.348 -1.329
    Other Liabilities, Total 26.559 30.587 28.764 27.237 32.607
    Total Equity 70.45 73.339 78.948 82.847 86.547
    Common Stock 441.299 440.28 439.148 437.151 435.818
    Retained Earnings (Accumulated Deficit) -367.742 -363.37 -357.016 -350.947 -344.184
    Other Equity, Total -3.107 -3.571 -3.184 -3.357 -5.087
    Total Liabilities & Shareholders’ Equity 113.205 123.664 131.148 135.922 144.52
    Total Common Shares Outstanding 170.174 170.093 169.886 169.748 169.727
    Preferred Stock - Non Redeemable, Net 0 0 0 0
    • Annual
    • Quarterly
    2022 2021 2020 2019 2018
    Net income/Starting Line -26.273 -43.019 -20.649 -11.709 -45.99
    Cash From Operating Activities 1.059 -23.561 -19.753 -31.947 -30.882
    Cash From Operating Activities 0.582 0.663 0.895 1.131 1.081
    Amortization 0.145 0.21 1.216 1.998 2.192
    Deferred Taxes
    Non-Cash Items 7.901 -2.511 -2.516 -21.464 11.197
    Cash Interest Paid 0.013 0.013 0.02 0.028 0.155
    Changes in Working Capital 18.704 21.096 1.301 -1.903 0.638
    Cash From Investing Activities -46.159 9.745 13.038 16.957 11.816
    Capital Expenditures -0.413 -0.354 -0.064 -0.44 -3.287
    Other Investing Cash Flow Items, Total -45.746 10.099 13.102 17.397 15.103
    Cash From Financing Activities 1.632 36.93 29.865 0.617 5.774
    Financing Cash Flow Items -0.123 -1.155 -0.383 0.654 0.161
    Issuance (Retirement) of Stock, Net 1.787 38.105 5.127 0.063 5.962
    Issuance (Retirement) of Debt, Net -0.032 -0.02 25.121 -0.1 -0.349
    Foreign Exchange Effects -0.873 -0.02 -0.063 0.07 0.006
    Net Change in Cash -44.341 23.094 23.087 -14.303 -13.286
    Mar 2023 Dec 2022 Sep 2022 Jun 2022 Mar 2022
    Net income/Starting Line -4.372 -26.273 -19.919 -13.85 -7.087
    Cash From Operating Activities -11.242 1.059 9.362 14.842 21.904
    Cash From Operating Activities 0.138 0.582 0.441 0.296 0.15
    Amortization 0.033 0.145 0.113 0.065 0.032
    Non-Cash Items 1.098 7.901 7.168 5.861 1.685
    Cash Interest Paid 0.002 0.013 0.013 0.009 0.005
    Changes in Working Capital -8.139 18.704 21.559 22.47 27.124
    Cash From Investing Activities 15.426 -46.159 -41.057 -0.143 -0.046
    Capital Expenditures -0.188 -0.413 -0.429 -0.143 -0.046
    Other Investing Cash Flow Items, Total 15.614 -45.746 -40.628 0 0
    Cash From Financing Activities 0.001 1.632 1.51 0.546 0.513
    Financing Cash Flow Items -0.037 -0.123 -0.112 -0.074 -0.008
    Issuance (Retirement) of Stock, Net 0.051 1.787 1.645 0.635 0.529
    Foreign Exchange Effects -0.1 -0.873 -0.795 -0.161 -0.042
    Net Change in Cash 4.085 -44.341 -30.98 15.084 22.329
    Deferred Taxes 0 0
    Issuance (Retirement) of Debt, Net -0.013 -0.032 -0.023 -0.015 -0.008
    Cash Taxes Paid 1.803
    Investor Name Investor Type Percent Outstanding Shares Held Shares change Holdings Date Turnover Rating
    Broadwood Capital, Inc. Hedge Fund 20.5293 34935485 0 2023-04-17 LOW
    Kingsley (Alfred D) Individual Investor 4.0249 6849242 0 2023-04-17 LOW
    The Vanguard Group, Inc. Investment Advisor/Hedge Fund 3.8225 6504938 397884 2023-03-31 LOW
    Defender Capital LLC Investment Advisor 3.0181 5136085 42550 2023-03-31 LOW
    BlackRock Institutional Trust Company, N.A. Investment Advisor 2.1625 3679968 -74234 2023-03-31 LOW
    Laurion Capital Management LP Hedge Fund 1.3974 2377940 0 2023-03-31 HIGH
    Prescott General Partners LLC Hedge Fund 1.0882 1851851 0 2023-03-31 LOW
    Raffles Capital Management, LLC Hedge Fund 0.9032 1536946 0 2023-03-31 LOW
    BofA Global Research (US) Research Firm 0.8484 1443779 1442750 2023-03-31 LOW
    Millennium Management LLC Hedge Fund 0.8239 1402123 1003084 2023-03-31 HIGH
    Geode Capital Management, L.L.C. Investment Advisor/Hedge Fund 0.7533 1282000 17591 2023-03-31 LOW
    JPMorgan Asset Management U.K. Limited Investment Advisor/Hedge Fund 0.5644 960512 0 2023-03-31 LOW
    Susquehanna International Group, LLP Investment Advisor 0.4797 816387 642768 2023-03-31 HIGH
    Bridgeway Capital Management, LLC Investment Advisor 0.4594 781766 0 2023-03-31
    Jane Street Capital, L.L.C. Research Firm 0.3505 596444 455199 2023-03-31 HIGH
    Citi Investment Research (US) Research Firm 0.272 462884 -14290 2023-03-31 MED
    State Street Global Advisors (US) Investment Advisor/Hedge Fund 0.2571 437496 0 2023-03-31 LOW
    MAI Capital Management, LLC Investment Advisor/Hedge Fund 0.2498 425115 -31702 2023-03-31 LOW
    ETF Managers Group, LLC Investment Advisor 0.1872 318596 -35395 2023-03-31 MED
    Morgan Stanley & Co. LLC Research Firm 0.1703 289882 169284 2023-03-31 MED

    Mengapa memilih Capital.com? Biarlah angka kami yang berbicara.

    Capital.com Group

    535K+

    Trader

    87K+

    Klien aktif per bulan

    $113M+

    Volume investasi per bulan

    $64M+

    Penarikan tiap bulan

    Trading calculator

    Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).

    Trade commission
    0
    • 1:1
    Leverage
    1:1
    • 20
    • 100
    • 500
    • 1000
    • 10000
    Investment
    Trade size (Leverage x Investement):
    Open

    Close

    Short Long
    Past performance is not a reliable indicator of future results
    Laba/Loss
    Industry: Biotechnology & Medical Research (NEC)

    2173 Salk Ave Ste 200
    CARLSBAD
    CALIFORNIA 92008-7354
    US

    Income Statement

    • Annual
    • Quarterly

    People also watch

    XRP/USD

    0.53 Price
    -0.140% 1D Chg, %
    Biaya inap posisi Long -0.0753%
    Biaya inap posisi short 0.0069%
    Waktu biaya inap 21:00 (UTC)
    Spread 0.00395

    US100

    14,473.70 Price
    +1.280% 1D Chg, %
    Biaya inap posisi Long -0.0255%
    Biaya inap posisi short 0.0032%
    Waktu biaya inap 21:00 (UTC)
    Spread 1.8

    Gold

    1,965.31 Price
    +1.310% 1D Chg, %
    Biaya inap posisi Long -0.0185%
    Biaya inap posisi short 0.0103%
    Waktu biaya inap 21:00 (UTC)
    Spread 0.30

    BTC/USD

    26,507.30 Price
    +0.430% 1D Chg, %
    Biaya inap posisi Long -0.0616%
    Biaya inap posisi short 0.0137%
    Waktu biaya inap 21:00 (UTC)
    Spread 60.00

    Masih mencari broker yang bisa Anda percayai?

    Bergabung dengan 535.000+ trader di seluruh dunia yang telah memilih trading bersama Capital.com

    1. Buat & verifikasi akun Anda 2. Lakukan deposit 3. Temukan trading Anda